U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467564) titled 'The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis' on March 09.
Brief Summary: This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
Study Start Date: Feb. 24
Study Type: OBSERVATIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: Dupi...